This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-516.SchmollHJVan CutsemESteinAValentiniVGlimeliusBHaustermansKESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingAnn Oncol201223247951610.1093/annonc/mds23623012255Search in Google Scholar
Cancer in Slovenia 2010. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2013.Cancer in Slovenia 2010Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia2013Search in Google Scholar
Zwitter M, Kovac V, Rajer M, Vrankar M, Smrdel U. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial. Anticancer Drugs 2010; 21: 662-8.ZwitterMKovacVRajerMVrankarMSmrdelUTwo schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trialAnticancer Drugs201021662810.1097/CAD.0b013e32833ab7a020453635Search in Google Scholar
Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node positive colon cancer. Ann Intern Med 2002; 136: 349-57.SundararajanVMitraNJacobsonJSGrannVRHeitjanDFNeugutAISurvival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node positive colon cancerAnn Intern Med20021363495710.7326/0003-4819-136-5-200203050-0000711874307Search in Google Scholar
Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 2004; 15: 1330-8.FolprechtGCunninghamDRossPGlimeliusBDi CostanzoFWilsJEfficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trialsAnn Oncol2004151330810.1093/annonc/mdh34415319237Search in Google Scholar
Köhne CH, Folprecht G, Goldberg RM, Mitry E, Rougier P. Chemotherapy in elderly patients with colorectal cancer. Oncologist 2008; 13: 390-402.KöhneCHFolprechtGGoldbergRMMitryERougierPChemotherapy in elderly patients with colorectal cancerOncologist20081339040210.1634/theoncologist.2007-004318448553Search in Google Scholar
Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.OcvirkJAdvances in the treatment of metastatic colorectal carcinomaRadiol Oncol2009431810.2478/v10019-009-0004-1Search in Google Scholar
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 29: 1842-7.Van CutsemERiveraFBerrySKretzschmarAMichaelMDiBartolomeoMSafety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnn Oncol2009291842710.1093/annonc/mdp23319406901Search in Google Scholar
Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010; 78: 329-39.KozloffMFBerlinJFlynnPJKabbinavarFAshbyMDongWClinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort studyOncology2010783293910.1159/00032022220733336Search in Google Scholar
Slavicek L, Pavlik T, Tomasek J, Bortlicek Z, Buchler T, Melichar B, et al. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterology 2014; 14: 53.SlavicekLPavlikTTomasekJBortlicekZBuchlerTMelicharBEfficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registryBMC Gastroenterology2014145310.1186/1471-230X-14-53398765024666582Search in Google Scholar
Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, et al. Comparing safety and efficacy of first-line irinotecan/fluoropirimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer. Cancer 2009; 115: 2617-29.JacksonNABarruecoJSoufi-MahjoubiRMarshallJMitchellEZhangXComparing safety and efficacy of first-line irinotecan/fluoropirimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancerCancer200911526172910.1002/cncr.2430519382200Search in Google Scholar
Price TJ, Zannino D, Wilson K, Simes J, Cassidy J, Van Hazel GA, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mytomycin C. Ann Oncol 2012; 23: 1531-6.PriceTJZanninoDWilsonKSimesJCassidyJVan HazelGABevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mytomycinC Ann Oncol2012231531610.1093/annonc/mdr488Search in Google Scholar
Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136:737-43.CassidyJSaltzLBGiantonioBJKabbinavarFFHurwitzHIRohrUPEffect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesJ Cancer Res Clin Oncol20101367374310.1007/s00432-009-0712-3Search in Google Scholar
Mesti T, Boshkoska BM, Kos M, Tekavčič M, Ocvirk J. The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: Discrepancy analysis between cost and reimbursement. Radiol Oncol 2015; 49: 200-8.MestiTBoshkoskaBMKosMTekavčičMOcvirkJThe cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: Discrepancy analysis between cost and reimbursementRadiol Oncol201549200810.2478/raon-2014-0046Search in Google Scholar
Kabbinavar FF, Schulz J, McCleod, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic col orectal cancer: results of randomized phase II trial. J Clin Oncol 2005; 23: 3697-705.KabbinavarFFSchulzJMcCleodPatelTHammJTHechtJRAddition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic col orectal cancer: results of randomized phase II trialJ Clin Oncol200523369770510.1200/JCO.2005.05.112Search in Google Scholar
Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open label, randomized phase 3 trial. Lancet Oncol 2013; 14: 1077-85.CunninghamDLangIMarcuelloELorussoVOcvirkJShinDBBevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open label, randomized phase 3 trialLancet Oncol20131410778510.1016/S1470-2045(13)70154-2Search in Google Scholar
Feliu J, Salud A, Safont MJ, Garcia-Girón C, Aparicio J, Vera R, et al. First-line bevacizumab and capecitabine-oxaliplatine in elderly patients with mCRC: GEMCAD phase II BECOX study. Br J Cancer 2014; 111: 241-8.FeliuJSaludASafontMJGarcia-GirónCAparicioJVeraRFirst-line bevacizumab and capecitabine-oxaliplatine in elderly patients with mCRC: GEMCAD phase II BECOX studyBr J Cancer2014111241810.1038/bjc.2014.346410295224946000Search in Google Scholar
Doat S, Thiébaut A, Samson S, Ricordeau P, Guillemont D, Mitry E. Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. Eur J Cancer 2014; 50: 1276-83.DoatSThiébautASamsonSRicordeauPGuillemontDMitryEElderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort studyEur J Cancer20145012768310.1016/j.ejca.2013.12.02624447833Search in Google Scholar
Ocvirk J, Rebersek M, Boc M. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. Anticancer Res 2011; 31: 1777-82.OcvirkJRebersekMBocMBevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRIAnticancer Res201131177782Search in Google Scholar
Ducreux M, Adenis A, Pignon J-P, François E, Chauffert B, Ichanté JL, et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2013; 49: 1236-45.DucreuxMAdenisAPignonJ-PFrançoisEChauffertBIchantéJLEfficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)Eur J Cancer20134912364510.1016/j.ejca.2012.12.01123352604Search in Google Scholar
